The 12/15-lipoxygenase (12/15LO) enzyme is widely distributed within the central nervous system. Previous work showed that this protein is upregulated in Alzheimer's disease (AD), and plays an active role in the development of brain amyloidosis in amyloid beta (Aβ)-precursor protein transgenic mice (Tg2576). In the present paper, we studied the effect of its pharmacologic inhibition on the AD-like phenotype of a mouse model with plaques and tangles, the triple-transgenic mice. Compared with mice receiving placebo, the group treated with PD146176, a specific 12/15LO inhibitor, manifested a significant improvement of their memory deficits. The same animals had a significant reduction in Aβ levels and deposition, which was secondary to a decrease in the β-secretase pathway. In addition, while total tau-soluble levels were unchanged for both groups, PD146176-treated mice had a significant reduction in its phosphorylation state and insoluble fraction, which specifically associated with decrease in stress-activated protein kinase/c-Jun N-terminal kinase activity. In vitro study showed that the effect on tau and Aβ were independent from each other. These data establish a functional role for 12/15LO in the pathogenesis of the full spectrum of the AD-like phenotype and represent the successful completion of the initial step for the preclinical development of 12/15LO inhibitors as novel therapeutic agents for AD.
INTRODUCTION
The lipoxygenases (LOs) form a large family of lipid-peroxidizing enzymes, which insert molecular oxygen into free and esterified polyunsaturated fatty acids. Among them, the mammalian 12/15lipoxygenase (12/15LO) is expressed in the central nervous system, 1, 2 where it oxidizes polyunsaturated fatty acids to produce 12-and 15-hydroxyeicosatetraenoic acids (12-HETE and 15-HETE) in different proportions. 3, 4 Compared with matched healthy controls, 12/15LO protein and activity levels have been shown to be elevated in the brains and cerebrospinal fluid of patients with Alzheimer's disease (AD). 5, 6 Previously, we have reported that brain genetic ablation or overexpression of 12/15LO in Aβ precursor protein (APP) transgenic mice, Tg2576, reduces or exacerbates amyloid beta (Aβ) pathology and behavioral deficits, respectively. 7, 8 However, because these mice mainly model only one of the two major pathological features of the AD phenotype, it would be of great scientific interest to investigate the role that this pathway may have on the other hallmark lesion, tau pathology and whether the two effects are linked.
With this goal in mind, in the present paper we evaluated the effect of pharmacological inhibition of 12/15LO in the tripletransgenic mice (3xTg), which develop amyloid plaques and tau tangles together with significant memory and learning deficits. 9 At the end of the study, we observed that mice receiving PD146176, a specific 12/15LO inhibitor, 10 manifested an improvement of their memory deficits, a significant decrease in the amount of Aβ plaques and neurofibrillary tangles when compared with controls. The changes in Aβ were associated with a downregulation of the β-secretase pathway, whereas the lower phosphorylation of tau was secondary to a selective decrease in the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/ JNK). In vitro studies confirmed these data and demonstrated that these effects were independent from each other.
Taken together our findings show for the first time the pleiotropic effect of 12/15LO on all three major AD pathological features: memory, Aβ and tau. They provide critical preclinical evidence that specific blockers of 12/15LO could be used as disease-modifying drugs for AD therapy.
MATERIALS AND METHODS

Mice and treatments
All animal procedures were approved by the Animal Care and Usage Committee, and in accordance with the National Institute of Health guidelines. The 3xTg mice harboring a mutant APP (KM670/671NL), a human mutant PS1 (M146V) knockin and tau (P301L) transgenes were used in this study. They were kept in a pathogen-free environment, on a 12-h light/dark cycle and had access to food and water ad libitum. A total of 23 mice were available for this study, with 5 female and 5 male mice in the PD146176 group, and 6 female and 7 male mice in vehicle control group. Starting at 3 months of age, mice were randomized to receive a selective and specific 12/15LO inhibitor PD146176 (80 mg kg − 1 ; n = 10) or vehicle (n = 13) in their regular rodent chow diet, which was prepared by a commercial vendor (Tecklad; Harlan Laboratories, Indianapolis, IN, USA), for 9 months until they were 12 months old. Diets were always matched for calories and changed every other day. At 12 months of age, they underwent behavioral testing and 2 weeks later were killed. During the study, both groups gained weight regularly, and no significant difference in weight was detected between the two groups. No macroscopic effect on the overall general health was observed in the animals receiving the active treatment. Post-mortem examination showed no sign of macroscopic pathology in any of the organs considered (that is, spleen, liver, thymus and ileum). At the time of killing the mice, brains were removed and dissected in two hemi-halves by mid-sagittal dissection. One-half was immediately stored at − 80°C for biochemistry assays, the other immersed in 4% paraformaldehyde in 0.1-M phosphate-buffered saline (pH 7.6) overnight for immunohistochemistry studies.
Behavioral tests
All animals were pre-handled for 3 days prior testing. They were tested in a randomized order, and all tests conducted by an experimenter blinded to the treatments.
Y-maze
The Y-maze is a behavioral test, which measures working memory and is based on the innate preference of a mouse to alternate arms when exploring a new environment. Mice typically prefer to explore a new arm of the maze rather than returning to the one that was previously explored. The Y-maze apparatus consisted of three arms 32 cm (long) × 10 cm (wide) with 26-cm walls (San Diego Instruments, San Diego, CA, USA). Testing was always performed in the same room and at the same time to ensure environmental consistency as previously described. 11, 12 Briefly, each mouse was placed in the center of the Y-maze and allowed to explore freely through the maze during a 5-min session. The sequence and total number of arms entered were video recorded. An entry into an arm was considered valid if all four paws entered the arm. An alternation was defined as three consecutive entries in three different arms (that is, 1, 2, 3 or 2, 3, 1 and so on). The percentage alternation score was calculated using the following formula: Total alternation number/total number of entries − 2) × 100. Furthermore, total number of arm entries was used as a measure of general activity in the animals. The maze was wiped clean with 70% ethanol between each animal to minimize odor cues.
Fear conditioning
This test provides a measure of memory by assessing a memory for the association between an aversive stimulus such as a mild foot shock and salient environmental cue. Fear-conditioning testing experiments were performed following methods previously described. 11, 12 Briefly, tests were conducted in a conditioning chamber (19 × 25 × 19 cm) equipped with black methacrylate walls, transparent front door, a speaker and grid floor (Start Fear System; Harvard Apparatus, Holliston, MA, USA). On day one, mice were placed into the conditioning chamber and allowed free exploration for 2 min in the white noise (65 Db) before the delivery of the conditioned stimulus tone (30 s, 90 Db, 2000 Hz) paired with a foot-shock unconditioned stimulus (2 s, 0.6 mA) through a grid floor at the end of the tone. A total of three pairs of conditioned stimulus-unconditioned stimulus pairing with a 30-s inter-trial interval were presented to each animal in the training stage. The mouse was removed from the chamber 1 min after the last foot shock and placed back in its home cage. The contextual fear-conditioning stage started 24 h after the training phase when the animal was put back inside the conditioning chamber for 5 min with white noise only (65 dB). The animal's freezing responses to the environmental context were recorded for 3 min. The tone fearconditioning stage started 2 h after the contextual stage. The animal was placed back to the same chamber with different contextual cues, including white wall, smooth metal floor, lemon extract drops, and dimmed yellowlight condition. After 3 min of free exploration, the mouse was exposed to the exactly same three conditioned stimulus tones with 30-s inter-trial interval in the training stage without the foot shock and its freezing responses to the tones were recorded for 3 min. One minute after the last tone, the mouse was brought back to the home cage.
Morris water maze
The Morris water maze is one of the most widely used tasks in behavioral neuroscience for studying spatial learning and memory. The apparatus used was a white circular plastic tank (122 cm in diameter) with walls 76 cm high, filled with water maintained at 22 ± 2°C, which was made opaque by the addition of a nontoxic white paint, and inside a removable, square (10 cm in side length) Plexiglass platform. The tank was located in a test room containing various prominent visual cues. Before the first trial of the first session, the mouse was placed for 10 s on the platform. Mice were trained to swim to the platform submerged 1.5 cm beneath the surface of the water and invisible to the mice while swimming. The platform was located in a fixed position, equidistant from the center and the wall of the tank. Mice were subjected to four training trials per day (inter-trial interval, 15 min). During each trial, mice were placed into the tank at one of four designated start points in a random order. Mice were allowed to find and escape onto the submerged platform. If they fail to find the platform within 60 s, they were manually guided to the platform and allowed to remain there for 10 s. Mice were trained to reach the training criterion of 20 s (escape latency). To control for overtraining, probe trials were run for each group, both as soon as they reached group criterion and after all groups had reached criterion.
Mice were assessed in the probe trial 24 h after the last training session and consisted in a 60-s-free swim in the pool without the platform. Each animal's performance was monitored using the Any-Maze video tracking system (Stoelting, Wood Dale, IL, USA), which provided data for the acquisition parameters (latency to find the platform and distance swam, distance traveled until first entry in the target platform zone) and the probe-trial parameter (number of entries to the target platform zone and time in quadrants).
Biochemical analyses
Mouse brain homogenates were sequentially extracted first in radioimmunoprecipitation (RIPA) buffer for the Aβ-soluble fractions, and then in formic acid for the Aβ-insoluble fractions as previously described. [10] [11] [12] [13] Aβ1-40 and Aβ1-42 levels were assayed by a sensitive sandwich ELISA kit (Wako Chemicals, Richmond, VA, USA). Homogenates were also assayed for levels of 12(S)HETE, the major metabolite of 12/15LO activation, by a sensitive specific immunoassay kit (Enzo Life Science, Farmingdale, NY, USA). Analyses were always performed in duplicate and in a coded manner.
Sarkosyl insolubility assay
The assay for insoluble tau was performed as previously described. 14 Briefly, ultracentrifugation and sarkosyl extraction (30 min in 1% sarkosyl) was used to obtain soluble and insoluble fractions of tau. Insoluble fractions were washed one time with 1% sarkosyl, then immunoblotted with HT-7 antibody.
Western blot analyses
RIPA extracts from brain homogenates were used for western blot analyses as previously described. [10] [11] [12] [13] Samples were electrophoresed on 10% Bis-Tris gels or 3-8% Tris-acetate gel (Bio-Rad, Richmond, CA, USA), according to the molecular weight of the target molecule, transferred onto nitrocellulose membranes (Bio-Rad), and then incubated with appropriate primary antibodies as indicated in Table 1 . In particular, C-terminal fragment-α (CTF-α) and CTF-β were blotted by using an APP-C-terminal antibody, can detect both of these two products at the same time. After three washings with Tween-Tris buffered saline, membranes were incubated with IRDye 800CW or IRDye 680CW-labeled secondary antibodies (LI-COR Bioscience, Lincoln, NE, USA) at 22°C for 1 h. Signals were developed with Odyssey Infrared Imaging Systems (LI-COR Bioscience). Beta-actin was always used as an internal loading control.
Immunohistochemistry
Immunostaining was performed as reported previously by our group. [10] [11] [12] [13] [14] Briefly, serial coronal sections were mounted on 3-aminopropyl triethoxysilane-coated slides. Every eighth sections from the habenular to the posterior commissure (8-10 sections per animal) was examined using unbiased stereological principles. The sections for testing Aβ were deparaffinized, hydrated, pretreated with formic acid (88%) and subsequently with 3% H 2 O 2 in methanol. The sections used for testing PHF-1, PHF-13, AT-8 and AT-180 were deparaffinized, hydrated and subsequently with 3% H 2 O 2 in methanol, and then antigen retrieved with citrate (10 mM). Sections were blocked in 2% fetal bovine serum before incubation with primary antibody overnight at 4°C (Wako Chemicals). After washing, sections were incubated with biotinylated anti-mouse IgG (Vector Labs, Burlingame, CA, USA) and then developed by using the avidin-biotin complex method (Vector Labs) with 3,3′-diaminobenzidine as a chromogen. Light microscopic images were used to calculate the area occupied by 
RESULTS
In vivo study
Pharmacologic blockade of 12/15LO improve cognition of 3xTg mice. In the Y-maze, the wild-type mice, 3xTg, and 3xTg mice receiving PD146176 did not show any significant differences in the total number of arm entries, suggesting that there were no differences in their general motor activity secondary to the genotype and treatment (Figure 1a ). However, compared with wild type, 3xTg mice manifested a significant reduction in alternations suggesting an impairment in their working memory, which was restored in the 3xTg mice receiving the drug (Figure 1a ). In the fear-conditioning test, no significant differences were observed among the three groups during the training phase ( Figure 1b ). However, compared with wild type, 3xTg mice had a significant reduction in the percentage of freezing in the cued but not the contextual recall paradigm, which was rescued by the administration of PD146176 (Figure 1b ). Mice were also tested for their reference spatial memory function by using the Morris water maze. In these studies, we performed visible platform training followed by hidden platform testing with four probe trials per day. All mice in each group were able to reach the training criterion within 4 days and were similarly proficient swimmers (data not shown). By contrast, in the probe trial, compared with wild type, 3xTg mice had significant increase in latency to first entry to the target zone and distance traveled until first entry in the target zone, and a decrease in the number of entries to the target zone ( Figure 1c ). However, administration of PD146176 to 3xTg mice resulted in significant improvement in the probe trial results, which were undistinguishable from the wild type group (Figure 1c ). Finally, there were no differences among the groups for the amount of time spent in the opposite target zone (data not shown).
Pharmacological blockade of 12/15LO reduces brain amyloidosis via the β-secretase pathway. Two weeks after the behavioral testing were completed, animals were killed and their brains were harvested for biochemistry and immunohistochemistry analyses.
First of all we wanted to assess compliance with the drug regimen by measuring brain levels of the major metabolic product of 12/15LO activation, 12(S)HETE. To this end we observed that compared with animals receiving placebo, mice treated with PD146176 had a significant reduction in the 12(S)HETE levels (373.0 ± 19.88 versus 209.8 ± 13.45 pg mg − 1 protein; Po 0.01). By contrast, no changes were observed when levels of LTB4, the metabolic product of another LO isoform, the 5LO, were assayed in the same brain tissues (data not shown).
Levels of both soluble (RIPA extractable) and insoluble (formic acid extractable) Aβ1-40 and Aβ1-42 in the brains of 3xTg mice receiving PD146176 were significantly reduced when compared to Po 0.0001, WT versus 3xTg; *P = 0.0003, 3xTg versus 3xTg PD). (b) Training, contextual and cued fear-conditioning memory responses for WT 3xTg mice receiving PD146176 (3xTg PD) or controls (3xTg; # P = 0.006, WT versus 3xTg; *P o0.05, 3xTg versus 3xTg PD). (c) Latency to first entry to the target platform zone, distance traveled until first entry in the target platform zone and number of entries to the target platform zone in the Morris water maze paradigm for WT 3xTg mice treated with PD146176 (3xTg PD) or vehicle (3xTg; # P o0.04, WT versus 3xTg; *P = 0.02, 3xTg versus 3xTg PD). Values represent mean ± s.e.m. (n = 8 for WT; n = 13 for 3xTg; n = 10 for 3xTg PD146176). controls (Figure 2a ). To determine the effect on brain Aβ deposition, the areas occupied by 4G8-immunopositive reactions were analyzed by immunohistochemistry. Comparison of the Aβ immunopositive areas between placebo and PD146176-treated groups revealed a statistically significant reduction of the amyloid burden in the treated mice (Figures 2b and c) . To understand the mechanism responsible for this effect on Aβ, next we investigated the metabolism of its precursor, the APP. To this end, steady-state levels of APP, α-secretase (ADAM-10), β-secretase (BACE-1) and the four components of the γ-secretase complex were assayed by western blot analysis. As shown in Figure 2d and e, levels of APP, ADAM-10 and its cleavage products, sAPPα and CTF-α, and the four components of the γ-secretase complex, PS1, Nicastrin, Pen-2 and APH-1 were unchanged between the two groups. By contrast, we observed that compared with controls mice receiving PD146176 had a significant decrease in the steady-state levels of BACE-1 and its cleavage products of APP, sAPPβ and CTF-β.
Pharmacological blockade of 12/15LO decreases tau phosphorylation via SAPK/JNK kinase. Next, we examined the effect of PD146176 on tau levels and metabolism in the two groups of mice. Compared with controls, mice chronically treated with the drug had a significant decrease in the insoluble tau fraction, while there were no changes in total soluble tau levels between the two groups (Figure 3a and b) . In addition, we found that the same animals manifested a significant reduction in its phosphorylated forms at different epitopes: S396, as recognized by the antibody PHF-13; S396/404, as recognized by the antibody PHF-1; S202/ T205, as recognized by the antibody AT8; T231/S235, as recognized by the antibody AT180 (Figure 3a and b) . By contrast, there were no significant changes for phosphorylated forms at T181, as recognized by the antibody AT270 (Figure 3a) . Immunohistochemical staining demonstrated decreased dendritic accumulations of the same phosphorylated epitopes in the brains of mice treated with PD146176 when compared with controls ( Figure  3c and d) .
To investigate the mechanism involved in this effect on tau phosphorylation, next we examined some of the kinases which are considered major regulators of its post-translational modifications. As shown in Figure 4 , no differences in the levels of total or phosphorylated GSK-3α and GSK-3β, cdk-5 pathway including p25 and p35 fragments, and the phosphatase PP2A were observed between the two groups of mice (Figure 4a and b) . By contrast, we found that brains of 3xTg mice treated with PD146176 had a significant reduction of the JNKs pathway as demonstrated by a significant decrease in the phosphorylated form of both p-JNK1 and p-JNK2/3, and in phosphorylated MKK4 (p-MKK4), an upstream activator of JNKs (Figure 4c and d) . However, no significant differences for total MKK4, total or phosphorylated p38, which is another member of MAPK pathway family, and for total or phosphorylated c-Jun, a downstream effector of JNK associated apoptotic signaling, were observed between the two groups. (Figure 4c and d) .
Pharmacological blockade of 12/15LO influences synaptic integrity and neuroinflammation. Since tau pathology has been correlated with the severity of dementia and memory impairments for which synaptic integrity is an important factor, we investigated whether pharmacological blockade of 12/15LO had any effect on this aspect of the AD-like phenotype. As shown in Figure 5 , we observed that compared with controls, steady-state levels of three distinct synaptic proteins, synaptophysin, post-synaptic density protein 95 and microtubule-associated protein 2, were significantly increased in the treated mice (Figure 4e and f ). In addition, we observed that compared with controls the same mice had a significant decrease in GFAP and CD45 immunoreactivity suggesting reduced activation of astrocytes and microglia cells, respectively (Figure 4e and f).
In vitro study 12/15LO modulates tau metabolism in an Aβ-independent manner. Because we observed that pharmacological blockade of 12/15LO reduces both Aβ levels and tau phosphorylation, next we wanted to assess whether these two effects were linked or independent from each other. To this end, we incubated neuro-2 A neuroblastoma expressing APP Swedish mutant neuronal cells directly with the metabolic product of 12/15LO enzymatic activation, 12/15-HETE, at a concentration known to increase the amount of Aβ formation in these cells, 8 in the presence of absence of a specific γ-secretase inhibitor, L685,485. As shown in Figure 5 , whereas as expected the drug L685,485 suppressed the formation of Aβ, it did not influence the effect of 12/15-HETE on tau phosphorylation.
DISCUSSION
The data presented in this study demonstrate that pharmacologic blockade of 12/15LO significantly ameliorates memory deficits, reduces Aβ levels and deposition, and decrease tau phosphorylation in the brains of the 3xTg mice. Taken together, they establish a functional role for 12/15LO in the pathogenesis of the full spectrum of the AD-like phenotype and represent the successful completion of the preclinical study for the development of 12/15LO inhibitors as viable potential therapeutic agents for AD.
Previous studies have supported a biologic link between 12/15LO and AD pathogenesis by showing that the activity and levels of this enzyme are significantly increased in AD patients, and that its genetic manipulation modulates the AD-like amyloidotic phenotype of APP transgenic mice, Tg2576. 15 However, because these mice mainly model only one of the two major pathological features of AD, the role that this pathway may have on the other hallmark lesion, tau neuropathology and whether the two effects are linked remains to be investigated.
With this goal in mind, we designed the pharmacological studies presented in the current paper using the 3xTg mice, which besides the memory impairments develop plaques and tangles neuropathology. Thus, using PD146176 an orally available selective 12/15LO inhibitor, 16 we first demonstrated that this therapeutic approach resulted in a significant improvement of their memory and learning performances, as demonstrated in three different experimental paradigms. As expected by their age, compared with wild type we observed that 3xTg mice had impaired responses in the Y-maze, fear conditioning and Morris water maze. However, compared with these 3xTg controls, mice receiving the drug had a significant increase in the percentage of alternation in the Y-maze, which reflects their immediate working memory. The same mice had an amelioration of their learning and memory ability, as assessed by their increased freezing time in the cued recall phase of the fear-conditioning paradigm. Finally, they manifested a better reference spatial memory function as assessed by the Morris water maze test.
Although we do not have data on the levels that the drug reached in the central nervous system of the treated mice, we confirmed a significant enzymatic inhibition of 12/15LO activity (its target) by measuring brain levels of its major metabolic product. Supporting a specific action of the drug, no changes were detected in the activity of another LO, the 5LO, in the same brain tissues. Considering that this enzyme is upregulated in AD post-mortem brains, 5 and that its metabolites act only locally, we believe that a peripheral inhibition of this enzyme as the mechanism responsible for the biological effect is very unlikely.
Consistent with the results of the behavioral tests, we found that compared with controls the same animals had a significant reduction in the amount and deposition of Aβ peptides. In particular, we observed that both soluble and insoluble Aβ1-40 and Aβ1-42 fractions were much lower in the brains of the drug-treated mice than in the placebo group. This decrease was also confirmed by an immunohistochemical approach, where we found significantly less Aβ deposition in the brain of mice receiving the active drug. In an effort to elucidate the mechanisms responsible for the Aβ reduction in the mice receiving PD146176, we assessed the steady-state levels of APP and the different proteases involved in its processing, that is, α-, βand γ-secretase, which ultimately results in the formation of Aβ peptides. First, we found that total APP, ADAM-10 and the four components of the γ-secretase complex protein levels were unaltered by the drug, suggesting that the in vivo biological action was not mediated by an effect on the Aβ precursor or on its αor γ-cleavage proteolytic pathways. By contrast, we observed that BACE-1 and its cleavage product sAPPβ were significantly reduced by this treatment confirming previous work showing the involvement of this pathway. 8 Beside Aβ pathology, AD is also characterized by the presence of abundant intracellular neurofibrillary tangles, which are formed mainly by the hyperphosphorylated microtubule-associated tau protein. 17 In the current study, we showed that pharmacological blockade of 12/15LO did not alter level of total soluble tau. By contrast, it significantly reduced the insoluble tau fraction which has been directly implicated in memory dysfunction and synaptic pathology, and the tau phosphorylation levels of several epitopes, which have been implicated in the development of neurofibrillary tangles. [18] [19] [20] To elucidate the mechanism for the PD146176-dependent reduction of tau phosphorylation, we assayed several putative kinases and phosphatases, which are considered major regulators of the post-translational modifications of tau. [21] [22] [23] In our study, we did not find significant differences for GSK-3, cdk-5 and tau phosphatase PP2A, between the two groups. By contrast, we found that 12/15LO pharmacological blockade affected specifically the SAPK/JNK kinase pathway, while had no effect of p38, which is another member of the MAPK family.
Previous studies showed that in AD the neuritic activation of SAPK/JNK is co-localized with increased tau phosphorylation, and that increased phospho-tau correlated with SAPK/JNK activation in the brains of mice exposed to stress. [24] [25] [26] [27] [28] In our study, we found that 12/15LO pharmacological blockade decreased activation of JKN pathway (less phospho-JNK but no changes in total JNK), and that this effect is likely to be mediated by the reduced activity of an upstream kinase. This hypothesis was corroborated by the decrease in the active form of MKK4 (MAPK kinase-4), an upstream activator of JNK, we found in the brains of the treated 3xTg mice.
Under normal conditions, tau is essential in stabilizing microtubules and axonal transport. However, increased phosphorylation of tau reduces its affinity and binding for microtubule and forms aggregates that accumulate in areas of the brain essential for learning and memory. Thus, previous studies have clearly shown that hyperphosphorylated tau plays a crucial role in synaptic plasticity and synaptic integrity. 29 Interestingly, in the current study, in association with the improvement in cognition we observed that 12/15LO pharmacological inhibition resulted also in a significant amelioration of biochemical markers of synaptic integrity.
Aside from Aβ, tau and synaptic pathology, activation of microglia and astrocytes is another important feature found consistently in the AD brain, and some work even suggests that these cells play a functional role in AD pathogenesis. 30 Interestingly, in our study we observed that expression levels of CD45 and GFAP, molecular markers of microglia and astyrocytes activation, respectively, were significantly reduced in the group of mice receiving the active drug.
Since data from transgenic mice support the hypothesis that Aβ can modify cellular metabolic events leading to phosphorylationspecific changes in tau 31 and considering that 12/15LO can also act as an endogenous modulator of Aβ, 8 it was possible that in our study the effect on tau was secondary to that on Aβ. However, based on our in vitro findings, we conclude that the effect of 12/15LO on tau phosphorylation is independent from it, because suppression of Aβ formation by a selective γ-secretase inhibitor did not influence the 12/15LO-dependent tau phosphorylation.
In summary, our study demonstrates the pleiotropic role that 12/15LO plays in the development of AD pathogenesis by influencing all three major aspects of the disease phenotype. These findings have important implications for the development of novel therapeutic approaches in which specific blockers of 12/15LO could be used as potential novel disease-modifying agents for AD.
